SLC25A10 and neoplasm: Interestingly, the gene-drug analysis showed that the sensitivity of ovarian cancer tumor cells to most chemotherapeutic agents was also diminished by low SLC25A10 expressions; however, Pluripotin, ARRY-162 and Pimasertib were more sensitive to low SLC25A10 cells.